Is infection with hypermutable Pseudomonas aeruginosa clinically significant? Adi Auerbach, Eitan Kerem, Marc Victor Assous, Elie Picard, Maskit Bar-Meir

Slides:

Advertisements

Similar presentations

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Advertisements

Christopher C. Miller, Christopher A

P. Whitaker, N. Shaw, J. Gooi, C. Etherington, S. Conway, D. Peckham

Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients Helle Krogh Johansen, Samuel.

William G. Flight, Jonathan Shaw, Susan Johnson, A

Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort Margaret Rosenfeld, Julia Emerson, Sharon McNamara,

Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection—A.

Epidemic Pseudomonas aeruginosa infection in patients with cystic fibrosis is not a risk factor for poor clinical Outcomes following lung transplantation

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Eitan Kerem, Michael Wilschanski, Nilsen L

A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study Maret L. Maliniak, Arlene A.

Cirrhosis and other liver disease in cystic fibrosis

The ease of breathing test tracks clinical changes in cystic fibrosis

Delayed publication of clinical trials in cystic fibrosis

Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia P.Ø. Jensen, C. Moser, A. Kharazmi,

A. Oliver, A. Mena Clinical Microbiology and Infection

Controlled clinical trials in cystic fibrosis — are we doing better?

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Anju Anand, Elizabeth Tullis, Anne Stephenson, Preyanka Abhyankar

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Cystic fibrosis mortality trend in Italy from 1970 to 2011

Molecular detection of an atypical, highly resistant, clonal Pseudomonas aeruginosa isolate in cystic fibrosis patients Deirdre Keating, Mary J. Crowe,

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

Implementation of European standards of care for cystic fibrosis �� Control and treatment of infection J.S. Elborn, M. Hodson, C. Bertram Journal of.

The Journal of Cystic Fibrosis: Sunny perspectives

A.H. Gifford Journal of Cystic Fibrosis

Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden Per Kristian Knudsen, Hanne.

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Inhalation solutions — Which ones may be mixed

Physiologic endpoints for clinical studies for cystic fibrosis

Characterisation of mutations and genotype–phenotype correlation in cystic fibrosis: Experience from India Shivaram S. Shastri, Madhulika Kabra, Sushil.

Sophia L. Markantonis, Anna Katelari, Eleni Pappa, Stavros Doudounakis

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?

Sally H. Pattison, Geraint B. Rogers, Martin Crockard, J

Anastasios Lekkas, Khin M. Gyi, Margaret E. Hodson

Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance P. Goncalves-Vidigal,

Nasal polyposis in lung transplant recipients with cystic fibrosis

Eradication failure of newly acquired Pseudomonas aeruginosa isolates in cystic fibrosis Malena Cohen-Cymberknoh, Noa Gilead, Silvia Gartner, Sandra.

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Paternity in men with cystic fibrosis: a retrospective survey in France Ingrid Duguépéroux, Dominique Hubert, Stéphane Dominique, Gil Bellis, Marc De.

Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions Gerard McCaughey,

Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic Amanda L. Griffiths, Danielle F. Wurzel,

Segregation of children with CF diagnosed via newborn screening and acquisition of Pseudomonas aeruginosa Karen O. McKay, Peter J. Cooper, Peter P. van.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Stationary biofilm growth normalizes mutation frequencies and mutant prevention concentrations in Pseudomonas aeruginosa from cystic fibrosis patients

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

L. Uppaluri, S.J. England, T.F. Scanlin Journal of Cystic Fibrosis

Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group† H. Goossens Clinical.

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic fibrosis Malena Cohen-Cymberknoh, Hannah Blau, David Shoseyov,

‘Peeling paint’ dermatitis as a presenting sign of cystic fibrosis

L. Nshimyumukiza, A. Bois, P. Daigneault, L. Lands, A. -M. Laberge, D

Beta-lactam allergy in adults with cystic fibrosis

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Patients with cystic fibrosis and normoglycemia exhibit diabetic glucose tolerance during pulmonary exacerbation Noa Nezer M. Sc, David Shoseyov, Eitan.

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern?

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

B. Martha, D. Croisier, A. Fanton, K. Astruc, L. Piroth, F. Huet, P

Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population Elaine.

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Is infection with hypermutable Pseudomonas aeruginosa clinically significant? Adi Auerbach, Eitan Kerem, Marc Victor Assous, Elie Picard, Maskit Bar-Meir Journal of Cystic Fibrosis Volume 14, Issue 3, Pages 347-352 (May 2015) DOI: 10.1016/j.jcf.2014.09.011 Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Distribution of the logarithmic transformation of mutation frequency in hypermutable and non-hypermutable isolates (N=96). Median value is presented for both groups. Journal of Cystic Fibrosis 2015 14, 347-352DOI: (10.1016/j.jcf.2014.09.011) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions